Does the use of nizatidine (Tazac) as a prokinetic agent improve gastric emptying in patients who have had an oesophagectomy for oesophageal cancer?
Cabrini Clinical Education and Research Institute
20 participants
Dec 1, 2004
Interventional
Conditions
Summary
The purpose of this project is to see whether nizatidine, a drug commonly used to treat peptic ulcers and reflux disease, may improve the emptying of the stomach in patients who have had an operation for oesophageal cancer. Participation in this project involves taking the trial medication for one week and having a special gastric empyting scan before and after one week of treatment with the drug. The scan involves a small dose of radiation which has been approved by the Department of Human Services, Radiation Safety Approval.
Eligibility
Plain Language Summary
Simplified for easier understanding
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Locations(1)
View Full Details on ANZCTR
For the most up-to-date information, visit the official listing.
ACTRN12605000454673